Grant number: IIRS-18-151 | Funding period: 2018 - 2022
Completed
EJ Lelliott, J Naddaf, K Ganio, J Michie, S Wang, L Liu, N Silke, A Ahn, KM Ramsbottom, AJ Brennan, AJ Freeman, S Goel, SJ Vervoort, CJ Kearney, PA Beavis, CA McDevitt, J Silke, J Oliaro
2024-12-01
Tumour immune evasion presents a significant challenge to the effectiveness of cancer immunotherapies. Recent advances in high-thr..
EJ Lelliott, KM Ramsbottom, MR Dowling, C Shembrey, T Noori, CJ Kearney, J Michie, IA Parish, MA Jordan, AG Baxter, ND Young, AJ Brennan, J Oliaro
2022-07-06
Cytotoxic lymphocytes are essential for anti-tumor immunity, and for effective responses to cancer immunotherapy. Natural killer c..
AJ Freeman, CJ Kearney, J Silke, J Oliaro
2021-12-01
Tumor necrosis factor (TNF) is a proinflammatory cytokine that is produced and secreted by cytotoxic lymphocytes upon tumor target..
AJ Freeman, SJ Vervoort, J Michie, KM Ramsbottom, J Silke, CJ Kearney, J Oliaro
2021-11-04
The success of cancer immunotherapy is limited to a subset of patients, highlighting the need to identify the processes by which t..
EJ Lelliott, IY Kong, M Zethoven, KM Ramsbottom, LG Martelotto, D Meyran, JJ Zhu, M Costacurta, L Kirby, JJ Sandow, L Lim, PM Dominguez, I Todorovski, NM Haynes, PA Beavis, PJ Neeson, ED Hawkins, GA McArthur, IA Parish, RW Johnstone
2021-10-01
Pharmacologic inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) are an approved treatment for hormone receptor–positive brea..
EJ Lelliott, GA McArthur, J Oliaro, KE Sheppard
2021-05-07
The recent advent of targeted and immune-based therapies has revolutionized the treatment of melanoma and transformed outcomes for..
CJ Kearney, SJ Vervoort, KM Ramsbottom, I Todorovski, EJ Lelliott, M Zethoven, L Pijpers, BP Martin, T Semple, L Martelotto, JA Trapani, IA Parish, NE Scott, J Oliaro, RW Johnstone
2021-02-19
Multimodal single-cell RNA sequencing enables the precise mapping of transcriptional and phenotypic features of cellular different..
EJ Lelliott, S Mangiola, KM Ramsbottom, M Zethoven, L Lim, PKH Lau, AJ Oliver, LG Martelotto, L Kirby, C Martin, RP Patel, A Slater, C Cullinane, AT Papenfuss, NM Haynes, GA McArthur, J Oliaro, KE Sheppard
2021-02-01
Combined inhibition of BRAF, MEK, and CDK4/6 is currently under evaluation in clinical trials for patients with melanoma harboring..
AJ Freeman, EJ Lelliott, J Oliaro
2020-12-01
Jessica Michie, Conor Kearney, Edwin D Hawkins, John Silke, Jane Oliaro
2020-01-14
One of the hallmarks of cancer cells is their ability to evade cell death via apoptosis. The inhibitor of apoptosis proteins (IAPs..
AJ Freeman, SJ Vervoort, KM Ramsbottom, MJ Kelly, J Michie, L Pijpers, RW Johnstone, CJ Kearney, J Oliaro
2019-09-10
Freeman et al. use a series of genome-wide loss-of-function genetic screens to identify genes that limit tumor sensitivity to kill..
J Michie, PA Beavis, AJ Freeman, SJ Vervoort, KM Ramsbottom, V Narasimhan, EJ Lelliott, N Lalaoui, RG Ramsay, RW Johnstone, J Silke, PK Darcy, I Voskoboinik, CJ Kearney, J Oliaro
2019-02-01
Chimeric antigen receptor (CAR) T-cell therapy has proven successful in the treatment of hematological malignancies, notably acute..